Anticoagulation Therapy Considerations in Factor VII Deficiency

Konkle B. Bleeding and thrombosis. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 457–64.

Lawson LH, Kalafatis M, Stram S, et al. A model for the tissue factor pathway to thrombin. J Biol Chem. 1994;269:23357–66.

Broze GJ Jr. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Annu Rev Med. 1995;46:103–12.

Bolton-Maggs PH. The rare inherited coagulation disorders. Pediatr Blood Cancer. 2013;60:S37–40.

Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39:684–92.

World Federation of Hemophilia. Report on the annual global survey. Montreal: World Federation of Hemophilia; 2010. p. 1–45.

Lapecorella M, Marian G. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 2008;14:1170–5.

Fair DS. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood. 1983;62:784–91.

Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734–44.

Goudemand J, Caron C, Dreyfus M, Sie P. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis. 2003;14:505–11.

Peyvandi F, Bolton-Maggs PHB, Batorova A, et al. Rare bleeding disorders. Haemophilia. 2012;18:148–53.

Mariani G, Herrmann FH, Dolce A, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005;93:481–7.

Benlakhal F, Mura T, Schved JF, et al. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost. 2011;9:1149–56.

Marty S, Barro C, Chatelain B, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14:564–70.

Paul B, Oxeley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX, and X concentrations in patients receiving long term warfarin. J Clin Pathol. 1987;40:94–8.

Baruch L. Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants. Postgrad Med. 2013;125:135–45.

Christensen TD, Jensen C, Larsen TB, Christiansen K, Sorensen B. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. Blood Coagul Fibrinolysis. 2009;20:358–65.

Davidson SJ, Turner N, Tillyer L. Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency. Blood Coagul Fibrinolysis. 2010;21:707–8.

Baltodano LE, Mungall DR, Watson DD. Management of a patient with atrial fibrillation and factor VII deficiency. Ann Pharmacother. 1998;32:1251–2.

Arellano-Rodrigo E, Gironella M, Nicolau I, et al. Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases. Thromb Haemost. 2009;101:402–4.

Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:546S–92S.

Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:700–52.

You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e531S–75S.

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation. 2014;64:2246–80.

Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.

Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50:5339–56.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49:761–72.

Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.

Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET-AF trial. Eur Heart J. 2014;35:1873–80.